Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19924794 | 1.00 | HRH1 (0.62) | HRH1ITGB3ITGA2BOPRK1CASP1 | |
| SCHEMBL23856080 | 0.81 | HRH1 (0.57) | HRH1ITGB3ITGA2BOPRK1IDO1 | |
| SCHEMBL23856082 | 0.81 | HRH1 (0.57) | HRH1ITGB3ITGA2BOPRK1IDO1 | |
| SCHEMBL5967157 | 0.81 | HRH1 (0.59) | HRH1ITGB3ITGA2BOPRK1CTSK | |
| SCHEMBL15689075 | 0.80 | ITGB3 (0.63) | HRH1ITGB3ITGA2BOPRK1CASP1 | |
| SCHEMBL7525533 | 0.77 | HRH1 (1.00) | HRH1ITGB3ITGA2BOPRK1CASP1 | |
| SCHEMBL7519514 | 0.77 | HRH1 (1.00) | HRH1ITGB3ITGA2BOPRK1CASP1 | |
| SCHEMBL26089886 | 0.75 | ITGB3 (0.58) | ITGB3ITGA2BCASP1BCHEACHE | |
| SCHEMBL26089884 | 0.75 | ITGB3 (0.58) | ITGB3ITGA2BCASP1BCHEACHE | |
| SCHEMBL954856 | 0.75 | CTSL (0.54) | ITGB3ITGA2BCASP1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066361-A1 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-27 | — | — | US | disclosed |
| US-12221444-B2 | 5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-02-11 | — | — | US | disclosed |
| CN-116942663-A | Compounds for the treatment of HBV | 葛兰素史克知识产权开发有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111433206-B | Compounds of formula (I) | 葛兰素史克知识产权开发有限公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-4180431-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-05-17 | — | — | EP | disclosed |
| EP-3692040-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-20220144834-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-05-12 | — | — | US | disclosed |
| WO-2021191827-A1 | TRIPEPTIDES DERIVATIVES FOR TREATING SARS-COV-2 INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-09-30 | — | — | WO | disclosed |
| US-20200255428-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-13 | — | — | US | disclosed |
| CN-111433206-A | Compound (I) | 葛兰素史克知识产权开发有限公司 | 2020-07-17 | — | — | CN | disclosed |
| WO-2018154466-A1 | DIHYDROQUINOLIZINONES AS ANTIVIRALS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018042343-A2 | COMPOUNDS THAT INHIBIT 3C AND 3CL PROTEASES AND METHODS OF USE THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221444-B2 | 5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use | HAVCR2, HBS1L, HBG1 | HRH1 47/4885ITGB3 3911/4885ITGA2B 3326/4885 |
| US-20250066361-A1 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | HAVCR2, HMBS, HBS1L | HRH1 152/4885ITGB3 3512/4885ITGA2B 2946/4885 |
| US-20220144834-A1 | Chemical Compounds | HAVCR2, HBS1L, HLA-B | HRH1 397/4885ITGB3 2895/4885ITGA2B 2889/4885 |
| US-20200255428-A1 | CHEMICAL COMPOUNDS | HAVCR2, HBS1L, HLA-B | HRH1 397/4885ITGB3 2895/4885ITGA2B 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.